- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00805103
Perfexion Brain Metastasis (HF-SRT)
December 28, 2016 updated by: University Health Network, Toronto
Hypofractionated Stereotactic Radiotherapy (HF-SRT) for Large-Volume Brain Metastases
Brain metastases occur in 20% to 40% of all patients with cancer , with an incidence 10 times higher than that of primary malignant brain tumors.
Patients with brain metastases have a poor prognosis with a median survival of 1-2 months with corticosteroids and 5-7 months with whole brain radiotherapy (WBRT).
Local control achieved with WBRT in patients with otherwise controlled systemic disease remains at issue.
A single high dose of radiation delivered with high precision to the target lesion (Stereotactic radiosurgery (SRS)), is considered standard care in salvage of recurrent lesions after WBRT.
SRS can destroy tumour with very little damage to surrounding tissue.
Research suggests that delivering radiotherapy in a number of smaller doses is more beneficial than receiving all of the radiotherapy in a single dose.
Brain metastases are well suited for SRS as they are often small, radiographically well-circumscribed, pseudospherical tumors that are noninfiltrative.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
With increasing volume of tumor, the dose of radiosurgery that can be safely delivered to recurrent oligo-metastases in the brain must be reduced.
However, reducing the dose of radiosurgery also compromises local control.
There is mounting evidence of a local control benefit to a hypofractionated approach in radiation delivery for brain metastases compared with single fraction radiosurgery.
Here we propose a novel therapeutic strategy that builds on this concept whereby time between each delivered fraction will enable us to measure and adapt to response, with the objective of reducing irradiated volumes and improving outcomes.
In general, the treatment of malignant tumors benefits from fractionation of the dose due to a number of radiobiological properties (redistribution, reoxygenation, repair) that distinguish, and select against, malignant lesions in the fractionation process.
Hypofractionated stereotactic radiotherapy (HSRT) is a method of delivering a highly conformal dose distribution in a few treatment sessions using a relocatable stereotactic frame.
HSRT may be an attractive alternative to SRS because it may 1) improve patient comfort by removing the invasive nature of SRS frames, 2) confer a radiobiologic advantage over single fraction treatment.
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 1-5 recurrent brain metastases after WBRT, and
- At least 1 lesions >2cm in maximum diameter
- ECOG 0-2
- Life expectancy >3months
- Age ≥ 18 years old
Exclusion Criteria:
- Edentulous patients
- Prior surgery or injury to hard palate
- Severe claustrophobia
- Contraindication to MRI
- Contraindication to IV contrast (Gadolinium) administration
- Other medical conditions that would preclude study investigations
- Prior radiosurgery to recurrent lesions
- Radiation cannot be delivered at the assigned dose level in a manner that respects OAR constraints (3.2.2.4.2.3.4) (e.g. lesions within brainstem or abutting optic structures)
- Any lesion >5cm in diameter, or total volume of tumor > 60cc
- Pregnant Women
- Men or women of childbearing potential who are unwilling to employ adequate contraception
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: (HFA-SRT) in Large-Volume Brain Metastases
|
Patients will be initially administered 8 Gy RT (level).
The dose at each level will be increase by 2 Gy up to level 4. If ≥ 2 of the patients in a dose cohort encounter a DLT, then that dose level will be declared the maximum administered dose.
An additional 3 patients will then be entered at the previous dose level and provided no more than one patient experiences a DLT, that level will be declared the maximum tolerated dose (MTD).
Up to 6 more patients can be treated at the given dose level while awaiting the results of 6 months of follow-up.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
This study aims to determine what the maximum tolerated dose of hypofractionated adaptive stereotactic radiotherapy (HFA-SRT) for recurrent brain metastases is.
Time Frame: every 3 months for 3 years
|
every 3 months for 3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The secondary outcome will be to evaluate the overall survival and change in tumour response.
Time Frame: every 3 months for 3 years
|
every 3 months for 3 years
|
Measure acute and late toxicities
Time Frame: every 3 months for 3 years
|
every 3 months for 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Caroline Chung, MD, University Health Network, Princess Margaret Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2008
Primary Completion (Actual)
March 1, 2016
Study Completion (Actual)
March 1, 2016
Study Registration Dates
First Submitted
December 8, 2008
First Submitted That Met QC Criteria
December 8, 2008
First Posted (Estimate)
December 9, 2008
Study Record Updates
Last Update Posted (Estimate)
December 29, 2016
Last Update Submitted That Met QC Criteria
December 28, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UHN REB 08-0602-C
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Metastases
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingRecurrent Brain Metastases | Progressive Brain MetastasesUnited States
-
AC Camargo Cancer CenterCarl Zeiss Meditec AGTerminatedBrain Metastases, Adult | Central Nervous System MetastasesBrazil
-
Rigshospitalet, DenmarkRecruitingCancer | Brain Metastases, AdultDenmark
-
Susanne RogersUniversity of Basel; Technical University of MunichRecruitingBrain Metastases, AdultSwitzerland
-
British Columbia Cancer AgencyVarian Medical SystemsRecruitingBrain Metastases, AdultCanada
-
IRCCS San RaffaeleRecruitingBrain Metastases, AdultItaly
-
AHS Cancer Control AlbertaRecruitingBrain Metastases, AdultCanada
-
University Health Network, TorontoRecruiting
-
Centre Francois BaclesseGroupement Interrégional de Recherche Clinique et d'Innovation; ANOCEF/IGCNORecruitingHemorrhagic Brain MetastasesFrance
-
Duke UniversityVarian Medical SystemsCompleted
Clinical Trials on Hypofractionated stereotactic radiotherapy
-
Huashan HospitalActive, not recruiting
-
Chang Gung Memorial HospitalRecruitingBrain Metastases, AdultTaiwan
-
Barretos Cancer HospitalWithdrawnCancer | MetastasisBrazil
-
National Taiwan University HospitalUnknownMetastasis of Malignant Neoplasm to Lymph NodeTaiwan
-
Centre Jean PerrinGORTECActive, not recruitingHead and Neck NeoplasmsFrance
-
Technical University of MunichRecruitingBrain Metastases | Resection CavityGermany
-
Barretos Cancer HospitalWithdrawn
-
Susanne RogersUniversity of Basel; Technical University of MunichRecruitingBrain Metastases, AdultSwitzerland
-
Hospices Civils de LyonCompletedProstatic AdenocarcinomaFrance
-
Centre Francois BaclesseAssociation de Neuro-Oncologues d'Expression FrancaiseActive, not recruitingBrain Metastasis | OligoprogressionFrance